ALNM Holds Gains Over Five Days
Alnylam Pharmaceuticals reported exciting stage 3 clinical trial results on September 20. Its drug, patisiran, treats a rare nerve disorder called familial amyloid polyneuropathy. Alnylam will seek regulatory approval for patisiran later this year.
Sonal sent out a level 2 alert at 7 am, and the next trade was at $93.50 during pre-market trading. The stock continued to surge throughout the day to a peak of $114.32. During the next four trading days, ALNM continued to trade in a range of $112-116.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!